Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial by Datoo, MS, Dicko, A, Tinto, H, Ouédraogo, J-B, Hamaluba, M, Olotu, A, Beaumont, E, Ramos Lopez, F, Natama, HM, Weston, S, Chemba, M, Compaore, YD, Issiaka, D, Salou, D, Some, AM, Omenda, S, Lawrie, A, Bejon, P, Rao, H, Chandramohan, D, Roberts, R, Bharati, S, Stockdale, L, Gairola, S, Greenwood, BM, Ewer, KJ, Bradley, J, Kulkarni, PS, Shaligram, U, Hill, AVS

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study by Schmit, N, Topazian, HM, Natama, HM, Bellamy, D, Traoré, O, Somé, MA, Rouamba, T, Tahita, MC, Bonko, MDA, Sourabié, A, Sorgho, H, Stockdale, L, Provstgaard-Morys, S, Aboagye, J, Woods, D, Rapi, K, Datoo, MS, Ramos Lopez, F, Charles, GD, McCain, K, Ouedraogo, J-B, Hamaluba, M, Olotu, A, Dicko, A, Tinto, H, Hill, AVS, Ewer, KJ, Ghani, AC, Winskill, P